Pretreatment regimens for adverse events related to infusion of amphotericin B.
about
Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsComparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trialEfficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry.Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.Antifungal and antiviral agents: a review.Lipid-based amphotericin B for the treatment of fungal infections.Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin BComparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patientsAmphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections?Fungal infections in older adults.Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management.Recommendations for the treatment of fungal pneumonias.Antifungal agent utilization evaluation in hospitalized neutropenic cancer patients at a large teaching hospital.Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safetyExperience with community-based amphotericin B infusion therapy.Identification of small molecules that disrupt vacuolar function in the pathogen Candida albicansCurrent options in antifungal pharmacotherapy.Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem celAntifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update.Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex.Efficacy and safety of current drug therapies for invasive aspergillosis.Invasive candidiasis: update on current pharmacotherapy options and future perspectives.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Variability in polyene content and cellular toxicity among deoxycholate amphotericin B formulations.Central nervous system histoplasmosis.Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study.Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics.Effects of amphotericin B and caspofungin on histamine expression.A multi-centre comparison of nursing staff time required for the preparation and administration of liposomal amphotericin B and amphotericin B deoxycholate vs. voriconazole.Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders.Cryptococcal Meningitis.
P2860
Q27025299-A3B89977-60D9-4671-A190-0788FA81DC25Q28359772-03250485-1D46-4F66-9693-C122EAA62D11Q30240770-0A435383-67B8-455D-A310-BF852986C1F3Q33371455-35416AAF-F637-473A-9231-924A4C3600B7Q33409652-5FBD8A4F-9836-4E26-B8AF-56607223F656Q33539956-7BF943F1-5735-43E7-B4DA-552B5716934AQ33604227-7299A81A-FC98-4920-8B59-3D808B70EC48Q33722067-4C9F1AE2-52EA-4DBF-9A59-04C329059819Q33976955-4D563825-7851-422C-85A8-AE3AEA0417BEQ34294886-F220A6E5-182D-4A87-A652-D73F3DE6A294Q34294904-A2B24D53-F803-4C52-A9F6-53822A0F0EFEQ34312894-7D695C5E-A34C-452E-ACC7-709650C2137CQ34350416-3F93CD0A-6708-4974-9F49-BF219C613DDBQ35183728-4A44F063-F64B-4B9B-8FF2-3B5D3BFAE9A0Q35687657-0F1A0F42-7381-4425-92F7-6625A1B4B7AAQ35825582-F3C395DC-9BA5-4232-96BF-079E1B114D19Q36130619-5927FF8C-43EB-4F2F-AB29-53D0CC5E810FQ36267368-57D23473-8A86-461B-88A0-B17925E9782FQ37151326-4A5AC741-CA90-4A62-A850-0898297DBF93Q37333175-9C424A8D-BA37-49EE-A493-E011951F5097Q37421528-7C46EAA0-E657-4A0B-A915-FE54829EF81DQ37641383-50FCAAB8-A825-42AC-9B74-23BC1CBF12EBQ37944001-2E6B675A-E8D3-41CE-AE08-B8FDF8804A81Q38110850-F62B8190-CCC0-45DA-A813-F77688A1A42FQ38193337-41F7A550-9689-4466-9DB7-201EEAABBCEDQ38284468-806705D6-16DC-411E-B898-E5F186A742F2Q40648601-9060C502-2222-4A8E-A731-BD8D8E4AD011Q44045562-CC2957E2-35E2-47B5-98B0-E229FD05DDF2Q44396642-3416F01F-2E4D-4280-8F80-36C632A63E49Q44440957-91A06A7D-4DF2-4D5C-B4F0-21AC4E0C90BEQ44551295-0399FD77-E79F-40BC-B322-3BF48F2CCCCDQ46239835-0C3756FA-3558-4B94-9240-ADBC0AD1E9A2Q46512137-4F40F94A-067D-4987-A2C9-042F3275B79FQ53888126-06EB2462-1419-4C83-A6C7-C3B69C8ED99B
P2860
Pretreatment regimens for adverse events related to infusion of amphotericin B.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Pretreatment regimens for adverse events related to infusion of amphotericin B.
@en
type
label
Pretreatment regimens for adverse events related to infusion of amphotericin B.
@en
prefLabel
Pretreatment regimens for adverse events related to infusion of amphotericin B.
@en
P2093
P356
P1476
Pretreatment regimens for adverse events related to infusion of amphotericin B.
@en
P2093
Goodwin SD
Grasela TH Jr
Walawander CA
P304
P356
10.1093/CLINIDS/20.4.755
P407
P577
1995-04-01T00:00:00Z